REFERENCE
Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König H-H.Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. PharmacoEconomics 26: 311-328, No. 4, Jan 2008
Rights and permissions
About this article
Cite this article
Ibandronic acid unlikely choice for IBD-related fracture prevention. Pharmacoecon. Outcomes News 551, 6 (2008). https://doi.org/10.2165/00151234-200805510-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805510-00015